CMAB vs IMAB in Metastatic Prostate Cancer

Longitudinal, Randomized, Open and Prospective Clinical Trial to Evaluate the Efficacy of Continuous vs Intermittent Maximum Androgen Blockade (CMAB vs IMAB) With Goserelin-Bicalutamide Combination in the Treatment of Hormonal naïve With Metastatic Prostate Cancer

Status

Withdrawn

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00255268

Enrollment

Registered

2005-11-18

Start date

2004-08-31

Completion date

Unknown

Last updated

2007-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Prostate Cancer

Brief summary

To evaluate the efficacy, safety and survival of two treatment regimens: Continuous Intermittent Maximum Androgen Blockade, using goserelin and bicalutamide in patients with prostate cancer. Primary endpoint is time to progression. Fifteen patients will be evaluated. QoL evaluation is also included.

Interventions

DRUGGoserelin

DRUGBicalutamide

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Histological diagnosis of D2 of Adenocarcinoma, * Naivety to treatment * Valuable bone metastasis

Exclusion criteria

* Hematological, liver or renal toxicity Grade IV * Severe and active infections

Design outcomes

Primary

Measure	Time frame
Time to progression	—

Secondary

Measure	Time frame
Safety	—
Quality of Life	—

Countries

Mexico

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026